ARA-290 (cibinetide)
Availability Clinical trials only
What it is
ARA-290, also called cibinetide, is an eleven amino acid peptide copied from a helix of erythropoietin. It was designed to hit the innate repair receptor, the tissue-protective arm of EPO signaling, without the red-blood-cell effects that make EPO itself dangerous. It is a pharmaceutical candidate rather than a wellness compound.
Why people take it
Almost nobody does, which is the honest starting point. The compound's audience has been people with small fiber neuropathy, the painful loss of the thinnest nerve fibers seen in sarcoidosis and in diabetes, where existing options manage pain without regrowing nerve. Interest inside longevity circles follows the broader idea that a tissue-protection signal might be useful past its original indication.
How it's delivered
Daily subcutaneous injection in the trial setting, under investigator supervision. Outside a trial there is no legitimate supply, no prescriber pathway, and no pharmacy that can lawfully compound it in the United States.
Where the evidence stands
Better than most peptides in this lane, and still short of an answer. A randomized phase 2 study in sarcoidosis patients reported improvement in neuropathy symptom scores at four weeks against placebo. A later 64-person phase 2b trial measured actual nerve regrowth, finding increased small nerve fiber abundance in the cornea and in skin biopsies, results consistent with disease modification rather than pain masking alone. The company reported a successful end-of-phase-2 meeting with FDA. What has not happened since is a phase 3 trial or an approval in any country, and FDA's compounding review placed cibinetide in the category of substances nominated without adequate supporting information.
Estimated cost
- No legitimate consumer price: not sold as a medicine anywhere
- Supplied free inside clinical trials
- Not covered by insurance
Who offers it
No clinic or telehealth provider in our map offers ARA-290, because there is nothing lawful to offer. Access runs through clinical trials, and anything sold online is a research chemical rather than a medicine.
Go deeper
The compound page, ARA-290 in the Peptide Explorer, is the depth layer. The lane guide, Peptides for Muscle Repair and Injury Recovery, covers how tissue-repair peptides are studied and what a real endpoint looks like.
Longevity.io is for educational purposes only and is not medical advice. An investigational compound with promising phase 2 data is still investigational. Anyone with neuropathy should raise trial options with a neurologist rather than source a research chemical.
Build your starting plan.
A few short questions, about two minutes. The Blueprint recommends where to start and explains why.
Build my Blueprint
